GBIO - Generation Bio GAAP EPS of -$0.66 misses by $0.04

• Generation Bio press release ( NASDAQ: GBIO ): Q2 GAAP EPS of -$0.66 misses by $0.04 .
• The company believes that its cash position of $312.2M will fund its operating plan into 2025.
• “We are advancing our leading non-viral genetic medicine platform to unlock the potential of durable, redosable non-viral DNA therapeutics, and we have made significant progress in establishing the proprietary technologies necessary to realize our vision,” said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. “This quarter, process development and scaling of rapid enzymatic synthesis ( RES ) for production of our closed-ended DNA (ceDNA) construct has allowed us to pursue a more flexible and capital efficient manufacturing strategy. In the remainder of the year, we plan to continue to develop our unique cell-targeted lipid nanoparticle (ctLNP) system for systemic delivery to hepatocytes, as well as for other therapeutic areas such as the retina and vaccines.”

For further details see: